Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01153815
First received: June 17, 2010
Last updated: October 4, 2012
Last verified: May 2012
  Purpose

This trial is a multicenter, double-blind, randomized, placebo-controlled study to compare GSK1358820 (Botulinum Toxin Type A, also known as "OnabotulinumtoxinA" or "Botox") with placebo on the efficacy and safety of treatment in poststroke subjects with focal wrist, finger and in some cases, thumb spasticity. Approximately 168 subjects will be enrolled. Subjects will receive a single treatment session of intramuscular GSK1358820 (Botulinum Toxin Type A, also known as "OnabotulinumtoxinA" or "Botox") '200U or 240U (if thumb spasticity is present)' or placebo in a randomization ratio of 1:1. The subjects will be observed until 12 weeks post injection. Outcome measures include changes from baseline at every post injection visit as measured on the Modified Ashworth Scale (MAS), Disability Assessment Scale (DAS) and Global Assessment Scale. The primary efficacy endpoint is the change from baseline at week 6 for wrist flexor muscle tone as measured on the Modified Ashworth Scale. Safety parameters will also be measured including adverse events, vital signs (pulse and blood pressure) and clinical laboratory tests (haematology, serum chemistry and urinanalysis).


Condition Intervention Phase
Cerebrovascular Accident
Drug: GSK1358820(Botulinum toxin type A)
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Change From Baseline at Week 6 for Wrist Flexor Muscle Tone as Measured on the Modified Ashworth Scale (MAS) [ Time Frame: Baseline (Day 0) and Week 6 ] [ Designated as safety issue: No ]
    The investigator, physiotherapist, or occupational therapist extended the participant's wrist as quickly as possible to grade flexor muscle tone. The MAS wrist score was calculated by using the 6-point MAS (0, 1, 1+ [regarded as 1.5], 2, 3, and 4; 0=no increase in muscle tone; 4=affected part[s] rigid in flexion/extension). Change from Baseline at Week 6 was calculated as the value at Week 6 minus the value at Baseline.


Secondary Outcome Measures:
  • Area Under the Curve (AUC) for the Change From Baseline at Weeks 6 and 12 for MAS Wrist Score [ Time Frame: Baseline (Day 0), Week 6, and Week 12 ] [ Designated as safety issue: No ]
    The MAS wrist score was assessed by using the 6-point MAS (0, 1, 1+ [regarded as 1.5], 2, 3, and 4; 0=no increase in muscle tone; 4=affected part[s] rigid in flexion/extension). Mean change from Baseline for the MAS wrist score was calculated as the value at Week 6 and Week 12 minus the value at Baseline. In a graph plotting time points on the horizontal axis (HA) and changes from Baseline on the vertical axis, the area surrounded by the MAS wrist score change curve and the HA was calculated and used as a summary index (AUC) for assessment of the MAS wrist score.

  • Change From Baseline at Weeks 1, 4, 8, and 12 for Wrist Flexor Muscle Tone as Measured on the MAS [ Time Frame: Baseline (Day 0) and Weeks 1, 4, 8, and 12 ] [ Designated as safety issue: No ]
    The investigator, physiotherapist, or occupational therapist extended the participant's wrist as quickly as possible to grade flexor muscle tone. The MAS wrist score was calculated by using the 6-point MAS (0, 1, 1+ [regarded as 1.5], 2, 3, and 4; 0=no increase in muscle tone; 4=affected part[s] rigid in flexion/extension). Change from Baseline at the indicated time points was calculated as the value at the indicated time points minus the value at Baseline.

  • Number of Participants Classified as Wrist Treatment Responders at All Post-injection Visits [ Time Frame: Weeks 1, 4, 6, 8, and 12 ] [ Designated as safety issue: No ]
    Wrist treatment responders were defined as participants with a decrease in wrist flexor muscle tone of at least one point on the MAS. The MAS wrist score was calculated by using the 6-point MAS (0, 1, 1+ [regarded as 1.5], 2, 3, and 4; 0=no increase in muscle tone; 4=affected part[s] rigid in flexion/extension).

  • Change From Baseline at Weeks 1, 4, 6, 8, and 12 for Finger Flexor Muscle Tone as Measured on the MAS [ Time Frame: Baseline (Day 0) and Weeks 1, 4, 6, 8, and 12 ] [ Designated as safety issue: No ]
    The investigator, physiotherapist, or occupational therapist extended the participant's finger as quickly as possible to grade the flexor muscle tone. The MAS finger score was calculated by using the 6-point MAS (0, 1, 1+ [regarded as 1.5], 2, 3, and 4; 0=no increase in muscle tone; 4=affected part[s] rigid in flexion/extension). Change from Baseline at the indicated time points was calculated as the value at Week 1, 4, 6, 8, and 12 minus the value at Baseline.

  • Change From Baseline at Weeks 1, 4, 6, 8 and 12 for Thumb Flexor Muscle Tone as Measured on the MAS [ Time Frame: Baseline (Day 0) and Weeks 1, 4, 6, 8, and 12 ] [ Designated as safety issue: No ]
    The investigator, physotherapist, or occupational therapist extended the participant's thumb as quickly as possible to grade the flexor muscle tone. The MAS thumb score was calculated by using the 6-point MAS (0, 1, 1+ [regarded as 1.5], 2, 3, and 4; 0=no increase in muscle tone; 4=affected part[s] rigid in flexion/extension). Change from Baseline at the indicated time points was calculated as the value at Week 1, 4, 6, 8, and 12 minus the value at Baseline.

  • Change From Baseline at Weeks 1, 4, 6, 8, and 12 for Principal Measure as Assessed on the Disability Assessment Scale (DAS) [ Time Frame: Baseline (Day 0) and Weeks 1, 4, 6, 8, and 12 ] [ Designated as safety issue: No ]
    The investigator assessed 4 areas of disability, hygiene, pain, dressing, and limb posture, using the 4-point DAS (0=No functional disability to 3=Severe disability). Prior to the first dose, the investigator, in consultation with the participant, selected 1functional disability item (which had to have a score of 2 or greater as measured on the DAS, indicating moderate to severe disability) from the 4 areas of disability and assessed it as a principal measure. Change from Baseline at the indicated time points was calculated as the value at Weeks 1, 4, 6, 8, and 12 minus the value at Baseline.

  • Global Assessment Scale (GAS) Score as Evaluated by the Physician at the Indicated Time Points [ Time Frame: Weeks 1, 4, 6, 8, and 12 ] [ Designated as safety issue: No ]
    The physician used the GAS to assess response to treatment at each visit after injection. The assessor was the same throughout the study period. GAS scores were assessed by using the 9-point GAS (-4, -3, -2, -1, -0, +1, +2, +3, +4; -4=very marked worsenig, -0=unchanged, +4=very marked improvement) at the indicated time points.

  • GAS Score as Evaluated by the Care Giver or the Participants at the Indicated Time Points [ Time Frame: Weeks 1, 4, 6, 8, and 12 ] [ Designated as safety issue: No ]
    The care giver or participants used the GAS to assess response to treatment at each visit after injection. The assessor was the same throughout the study period. GAS scores were assessed by using the 9-point GAS (-4, -3, -2, -1, -0, +1, +2, +3, +4; -4=very marked worsening, -0=unchanged, +4=very marked improvement) at the indicated time point.


Enrollment: 170
Study Start Date: April 2010
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: placebo
Sodium chloride
Drug: placebo
placebo
Experimental: GSK1358820(Botulinum Toxin Type A)
GSK1358820 (Botulinum Toxin Type A, also known as "OnabotulinumtoxinA" or "Botox")
Drug: GSK1358820(Botulinum toxin type A)
GSK1358820 (Botulinum Toxin Type A, also known as "OnabotulinumtoxinA" or "Botox")
Other Names:
  • OnabotulinumtoxinA
  • Botox

Detailed Description:

The primary objective of this study is to confirm the superior efficacy of a single treatment session with GSK1358820 (Botulinum Toxin Type A, aslo known as "OnabotulinumtoxinA" or "Botox") '200U or 240U (if thumb spasticity is present)' over placebo in subjects with post-stroke upper limb spasticity of both wrist and fingers flexors as measured on the Modified Ashworth Scale (MAS).

This trial is a multicenter, double-blind, randomized, placebo-controlled, parallel group study comparing GSK1358820 (Botulinum Toxin Type A, also known as "OnabotulinumtoxinA" or "Botox") to placebo for the treatment of subjects with focal wrist, finger and in some cases, thumb spasticity post-stroke. Approximately 168 subjects will be enrolled. Subjects will receive a single treatment session with intramuscular injections of GSK1358820 (Botulinum Toxin Type A, also known as "OnabotulinumtoxinA" or "Botox") '200U or 240U (if thumb spasticity is present)' or placebo in a randomization ration of 1:1. The subjects will be observed until 12 weeks post injection.

Each completed subject will attend 7 clinic visits. The maximum study duration is 13 weeks per subject. The study includes a 1 week pretreatment period, during which the screening visit (visit 1) is to take place. Only one upper limb (meeting inclusion/exclusion criteria) will be evaluated and treated in the study. Subjects will receive a single intramuscular treatment with either investigated drug or placebo at day 0 (visit 2). There will be five post-injection follow-up visits at weeks 1, 4, 6, 8 and 12 (visits 3 to 7). Week 6 (visit 5) is designated as the primary visit for determining efficacy.

The primary endpoint is the change from baseline at week 6 for wrist flexor muscle tone as measured on the Modified Ashworth Scale (MAS). The secondary endpoints include The secondary endpoints include the area under curve (AUC) for the MAS wrist score change from baseline, change from baseline for wrist/finger/thumb flexor muscle tone as measured on MAS, Disability Assessment Scale and Global Assessment Scale. The safety measures include adverse events, clinical laboratory tests and pulse, blood pressure.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subjects eligible for enrolment in the study must meet all of the following criteria:

  1. Subjects with upper limb spasticity who are at least 6 months post stroke and present with spasticity of both the wrist and fingers in the study limb.
  2. Wrist flexor muscle tone of 3 or greater and finger flexor muscle tone of 2 or greater as measured on MAS (0 to 4).
  3. At least one functional disability item (i.e., hygiene, dressing, pain, or cosmesis) with a rating of 2 or greater on DAS (0 to 3).
  4. If using oral anti-spasticity medications, must be stable for at least 1 month prior to study enrolment
  5. If using physical therapy, must be stable for at least 1 month prior to study enrolment.
  6. Male or female 18 to 75 years old at the time of informed consent.
  7. >=40kg in weight.
  8. QTc criteria: (either QTcb or QTcf, machine or manual overread, males or females); include the following details as appropriate: QTc<450 millisecond (msec) or <480msec for subjects with Bundle Branch Block-values based on either single electrocardiogram (ECG) values or triplicate ECG averaged QTc values obtained over a brief recording period.
  9. Liver function tests: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2xULN; alkaline phosphatase and bilirubin ≤1.5xULN (isolated bilirubin >1.5ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
  10. In the opinion of the investigator, subject must clearly understand the intent of the study and be willing and able to comply with study instructions and complete the entire study.
  11. Informed consent has been obtained.

Exclusion Criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:

  1. Presence of fixed contracture of the study limb (absence of passive range of motion).
  2. Profound atrophy of muscles to be injected (in the investigators opinion).
  3. Infection or dermatological condition at the injection sites.
  4. Significant inflammation in the study limb limiting joint movement.
  5. History of or planned treatment for spasticity with phenol or alcohol block in the study limb.
  6. History of or planned surgical intervention for spasticity of the study limb.
  7. History (within 3 months of qualification) of or planned (during study period) casting of the study limb.
  8. Participation in another clinical study currently, or within the 30 days immediately prior to enrolment.
  9. Previous or current botulinum toxin therapy of any serotype.
  10. Planned or anticipated initiation of new antispasticity medications during the clinical study.
  11. Any medical condition that may put the subject at increased risk with exposure to GSK1358820, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other disorder that might have interfered with neuromuscular function.
  12. Concurrent use of aminoglycoside antibiotics or other agents that might interfere with neuromuscular function. A full list of prohibited medications that interfere with neuromuscular transmission is provided as Appendix 1.
  13. Current treatment for spasticity with an intrathecal baclofen.
  14. Females who are pregnant, nursing, or planning a pregnancy during the study period, or females of childbearing potential, not using a reliable means of contraception.
  15. Known allergy or sensitivity to study medication or its components.
  16. Bedridden subjects.
  17. Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  18. Presence of clinically unstable severe cardiovascular, renal or respiratory disease.
  19. Investigator's opinion that the subject has a concurrent condition(s) that may put the subject at significant risk, may confound the study results, or may interfere significantly with the conduct of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01153815

Locations
China, Guangdong
GSK Investigational Site
Guangzhou, Guangdong, China
China, Heilongjiang
GSK Investigational Site
Haerbin, Heilongjiang, China, 150001
China, Hubei
GSK Investigational Site
Wuhan, Hubei, China, 430060
China, Jiangsu
GSK Investigational Site
Suzhou, Jiangsu, China, 215004
China, Liaoning
GSK Investigational Site
Shenyang, Liaoning, China, 110001
China, Sichuan
GSK Investigational Site
Chengdu, Sichuan, China, 610041
China
GSK Investigational Site
Beijing, China, 100050
GSK Investigational Site
Hangzhou, China, 310016
GSK Investigational Site
Shanghai, China, 200040
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01153815     History of Changes
Other Study ID Numbers: 112958
Study First Received: June 17, 2010
Results First Received: April 19, 2012
Last Updated: October 4, 2012
Health Authority: China: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
efficacy
Spasticity, Post-Stroke
safety
Botulinum toxin type A
placebo
spasticity

Additional relevant MeSH terms:
Cerebral Infarction
Muscle Spasticity
Stroke
Brain Diseases
Brain Infarction
Brain Ischemia
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Muscle Hypertonia
Muscular Diseases
Musculoskeletal Diseases
Nervous System Diseases
Neurologic Manifestations
Neuromuscular Manifestations
Signs and Symptoms
Vascular Diseases
Botulinum Toxins
Botulinum Toxins, Type A
Anti-Dyskinesia Agents
Central Nervous System Agents
Neuromuscular Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014